Eichhorst, Barbara (2022). Ibrutinib frontline in young patients with CLL. Blood, 140 (2). S. 80 - 82. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Full text not available from this repository.Abstract
In this issue of Blood, Shanafelt et al(1) confirm the continued superiority of ibrutinib plus rituximab (IR), compared with the prior standard treatment, fludarabine, cyclophosphamide, and rituximab (FCR), for fit patients with chronic lymphocytic leukemia (CLL). In addition, they report relevant data on the tolerability of continuous treatment with BTK inhibitor.
Item Type: | Journal Article | ||||||||
Creators: |
|
||||||||
URN: | urn:nbn:de:hbz:38-656953 | ||||||||
DOI: | 10.1182/blood.2022016535 | ||||||||
Journal or Publication Title: | Blood | ||||||||
Volume: | 140 | ||||||||
Number: | 2 | ||||||||
Page Range: | S. 80 - 82 | ||||||||
Date: | 2022 | ||||||||
Publisher: | AMER SOC HEMATOLOGY | ||||||||
Place of Publication: | WASHINGTON | ||||||||
ISSN: | 1528-0020 | ||||||||
Language: | English | ||||||||
Faculty: | Unspecified | ||||||||
Divisions: | Unspecified | ||||||||
Subjects: | no entry | ||||||||
Uncontrolled Keywords: |
|
||||||||
URI: | http://kups.ub.uni-koeln.de/id/eprint/65695 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
View Item |